Focus: Lead Biologics International is a Swedish biotech company specializing in antibody treatments for cancer, focused on the oncology therapeutic area.
Profile data last refreshed 17h ago · AI intelligence enriched 2mo ago
No open roles listed right now. Follow Lead Biologics International to get notified when they start hiring — the background below is worth knowing for when they do.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
No open positions listed yet. Check their careers page directly.
Help build intelligence for Lead Biologics International
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Lead Biologics International's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Based on last 4 crawl cycles
Recent peer-reviewed publications with author affiliations at this company
MicroRNAs as master regulators of macrophage function in atherosclerosis: From polarization to therapeutic potential.
Cryo-EM structures of Drosophila OR67d-Orco complexes reveal insect pheromone sensing mechanism.
Structure-Based Design and Optimization of Novel, Potent and Selective Covalent FGFR2/3 Inhibitors with a Tricyclic Core.
Identification of a NRP with the ability to destroy cell membrane of Staphylococcus epidermidis from Rhodococcus genomes database.
Economic Impact of Timely Systemic Treatment of Psoriatic Disease in Comorbidity Risk Reduction: Literature Review and (Early) Economic Assessment.
Showing 5 of 10 publications
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo